Zacks Investment Research upgraded shares of Henry Schein In (HSIC) from NEUTRAL to OUTPERFORM on November 20, 2014, with a target price of $159.00.
Henry Schein posted a solid third quarter with adjusted EPS of $1.34 in the third-quarter of 2014 increased 9.8% year over year and also beat the Zacks Consensus Estimate by 2.3%. Revenues rose 11.7% to $2.62 billion, edging past the Zacks Consensus Estimate by 2.54%. Animal Health continued to perform well while the core dental business picked up. The recent strategic acquisitions are expected to add value to the business. With the animal health market growing at a rapid pace and showcasing favorable trends, we are confident about further sales improvement. Henry Schein is currently investing in growth opportunities for new product launch, improve operating margin and develop new technology solutions that will improve the customer experience and elevate Henry Schein's position in the marketplace. We upgrade the stock to Outperform.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Henry Schein In (HSIC),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment